Actinium Pharmaceuticals (ATNM) Rating Increased to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a hold rating to a buy rating in a research report report published on Tuesday morning. Zacks Investment Research currently has $0.75 target price on the biotechnology company’s stock.

According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “

Several other equities research analysts have also recently issued reports on ATNM. B. Riley set a $3.00 price objective on Actinium Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, December 27th. Maxim Group set a $3.00 price objective on Actinium Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, December 27th. HC Wainwright reiterated a buy rating and issued a $6.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Finally, Roth Capital reiterated a buy rating and issued a $6.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Five analysts have rated the stock with a buy rating, Actinium Pharmaceuticals presently has an average rating of Buy and a consensus target price of $3.75.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) traded up $0.02 during trading hours on Tuesday, hitting $0.73. The stock had a trading volume of 589,600 shares, compared to its average volume of 577,125. Actinium Pharmaceuticals has a 52-week low of $0.54 and a 52-week high of $1.72. The firm has a market cap of $56.02, a PE ratio of -1.55 and a beta of 41.30.

COPYRIGHT VIOLATION NOTICE: “Actinium Pharmaceuticals (ATNM) Rating Increased to Buy at Zacks Investment Research” was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2018/01/12/actinium-pharmaceuticals-atnm-rating-increased-to-buy-at-zacks-investment-research.html.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply